INmune Bio, Inc.
INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinomā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.53
Price-3.17%
-$0.05
1Y
Price
Market Cap
$40.675m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$50k
+257.1%
1y CAGR+35.9%
3y CAGR+53.6%
5y CAGREarnings
-$49.887m
-18.5%
1y CAGR-22.9%
3y CAGR-14.7%
5y CAGREPS
-$2.13
-0.9%
1y CAGR-12.4%
3y CAGR-4.5%
5y CAGRBook Value
$25.378m
$33.358m
Assets$7.980m
Liabilities$1.080m
DebtDebt to Assets
3.2%
-
Debt to EBITDAFree Cash Flow
-$31.550m
+5.4%
1y CAGR-41.9%
3y CAGR-19.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company